Hypocholesterolemia friend or foe?
Stefano Romeo, Arca Marcello, Mathilde Di-Filippo, Luca Valenti
September 20, 2022 | Webinars on-demand
Should we target inflammation?
Paul Ridker
May 25, 2022 | Plenary 3: From lifestyle to designer therapies, 90th EAS Congress 2022 | #
Lomitapide in the long-term real-world management of HOFH – effectiveness, tolerability, and hepatic safety data from the pan-european study
Laura D'Erasmo
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Developing medicines that mimic resistance mutations
Sekar Kathiresan
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Artificial Intelligence assisted diagnostics of atherosclerotic vascular disease
Charalambos Antoniades
May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies | #
New World of targeted therapies (targets, delivery systems,new molecules) – Discussion and Q&A
Franco Bernini, Nathan Wong, Sekar Kathiresan, Megan Levings, Hana Totary-Jain, Alexis Hofherr, Laura D'Erasmo
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Targeting non-coding RNAs
Kathryn Moore
May 25, 2022 | 90th EAS Congress 2022, Plenary 3: From lifestyle to designer therapies
Etesian: a phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia
Alexis Hofherr
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Cell based therapies in atherosclerosis
Megan Levings
May 25, 2022 | New World of targeted therapies (targets and delivery systems and new molecules), 90th EAS Congress 2022
Nonpharmacologic approaches to promote population cardiovascular health
Salim Yusuf
May 25, 2022 | Plenary 3: From lifestyle to designer therapies, 90th EAS Congress 2022 | #